Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. reports that the Court of Milan has revoked a preliminary order that had suspended the effectiveness of the amendment to its corporate purpose in Article 4 of its bylaws, approved at the extraordinary shareholders’ meeting held on October 29, 2025.
By order dated July 9, 2026, the Court granted the Company’s precautionary appeal, found that the Company’s interest in maintaining the amendment currently outweighs the alleged prejudice claimed by minority shareholders, and ordered removal of the suspension’s registration from the Italian Companies Register. The corporate purpose amendment is once again fully effective, while the underlying civil action challenging the May 2, 2024 and October 29, 2025 resolutions remains pending, and the Company intends to continue to vigorously defend their validity.
Genenta Science S.p.A. reports outcomes from its June 2026 shareholder meetings and the completion of a strategic acquisition. Shareholders approved the statutory financial statements for the year ended December 31, 2025 and appointed five directors to the Board, with co-founder and CEO Pierluigi Paracchi re-appointed as Chairman.
The Extraordinary Shareholders’ Meeting, which includes proposals to change the corporate name to Saentra Forge S.p.A., delegate to the Board authority to increase share capital under Articles 2443 and 2420-ter of the Italian Civil Code, and execute a share reverse split, was adjourned to July 29, 2026 (first call) and July 30, 2026 (second call) to allow additional shareholder engagement. The record date for voting eligibility remains unchanged.
Genenta also confirms closing of its previously announced transaction to acquire a majority equity interest in Sòphia High Tech S., after receiving the required authorization under Italian “Golden Power” legislation and satisfying all other closing conditions. The transaction terms remain as described in the company’s April 23, 2026 Form 6-K.
Genenta Science S.p.A. describes an interim order from the Court of Milan concerning two past shareholder resolutions. The court declined to suspend the May 2, 2024 resolution introducing a multiple voting rights mechanism, so that mechanism and related voting rights remain in effect.
The court temporarily suspended the October 29, 2025 resolution that amended Genenta’s corporate purpose, citing concerns that the provision is overly broad and linked to future “Golden Power” legislative changes. Existing transactions, including those involving ATC and Sophia High Tech, are not affected.
Genenta has appealed the suspension before a panel of the Court of Milan, with a hearing scheduled for July 9, 2026. Depending on the outcome, the corporate purpose amendment may remain effective or be revised and resubmitted to shareholders.
Genenta Science S.p.A. filed a Form 6-K describing new arrangements with its Chief Executive Officer and General Manager, Pierluigi Paracchi. The company entered into a Parachute Agreement that provides a lump-sum severance payment equal to twelve months of his last gross remuneration under certain qualifying termination events.
In addition, he would receive an amount equal to his target annual bonus opportunity, up to 40% of his annual gross remuneration. Genenta also amended the non-compete covenant in his employment agreement, narrowing the definition of competitive activities to specified areas within the pharmaceutical, biotechnology, molecular and cellular medicine, genetics, and diagnostics sectors.
Genenta Science S.p.A. has called an all-virtual ordinary and extraordinary shareholders’ meeting for June 29, 2026, with a possible second call on June 30, 2026. Shareholders will vote on approving the financial statements for the year ended December 31, 2025, appointing a new Board of Directors (including compensation), and authorizing the purchase and disposal of treasury shares.
They will also consider changing the corporate name to Saentra Forge S.p.A., delegating authority to the Board to increase share capital and/or issue convertible bonds, and approving a reverse stock split of the ordinary shares within a shareholder-approved range. The Board would later set the final ratio and decide whether to implement the reverse split after determining that the company has not achieved stable compliance with Nasdaq listing requirements.
Genenta Science S.p.A. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share for continued listing.
Nasdaq notified Genenta on April 10, 2026 that the closing bid price of its American Depositary Shares had been below $1.00 per share for 30 consecutive business days, placing the company out of compliance. Nasdaq has now determined that from June 1, 2026 through June 12, 2026, the closing bid price was at or above $1.00 per share for 10 consecutive business days, restoring compliance and closing the matter.
Genenta Science S.p.A. completed its acquisition of the remaining 80.5% equity ownership of A.T.C. S. from the existing A.T.C. shareholders. This follows an earlier Investment Agreement and is governed by an Amendment Agreement dated May 25, 2026, approved by the board on May 18, 2026.
The transaction was finalized before an Italian notary on May 29, 2026, making A.T.C. fully owned by Genenta. The parties remain subject to provisions such as a lock-up period, put option, and call option, as outlined in the A.T.C. Amendment Agreement, which is filed as Exhibit 10.1.
Genenta Science S.p.A. has approved the termination of its amended and restated license agreement with Ospedale San Raffaele, which covered certain technology and intellectual property rights licensed to the company. The termination will end the licenses and option rights granted under the agreement, except for surviving and wind-down provisions and any accrued obligations.
The company does not expect any material termination fee or penalty beyond obligations already accrued. Management reached this decision after reviewing strategic priorities and plans to redirect resources to ongoing business and strategic initiatives. Genenta will continue to support and monitor its active glioblastoma multiforme clinical trial, where two patients are currently under observation.
Genenta Science S.p.A. shareholders have filed a joint Schedule 13D reporting a coordinated stake in the company. Eleven investors, including individuals and Italian investment companies, report beneficial ownership of 5,433,910 Ordinary Shares and ADS, representing about 23.0% of shares and 31.5% of total voting power as of March 19, 2026.
The group was formed under a Shareholders' and Joint Filing Agreement dated May 4, 2026, with a five‑year term. They state their goal is to promote stability in Genenta’s biotech-focused strategic direction and to oppose recent amendments expanding the corporate purpose to broadly reference Italian “Golden Power” sectors. Certain members have already brought court proceedings in Milan challenging these corporate changes.
The shareholders plan to coordinate voting at shareholders’ meetings, including presenting a joint slate for the board of directors and statutory auditors, and indicate they are not seeking to acquire additional shares in connection with these objectives. They report having invested approximately $18.6 million (about €15.9 million) in Genenta over time using personal or working capital.
Genenta Science S.p.A. reported that Chief Executive Officer Pierluigi Paracchi received a grant of stock options for 100,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
According to the grant terms, the options vest in equal monthly installments over three years beginning March 30, 2026, meaning the award becomes exercisable gradually rather than all at once. After this grant, Paracchi holds stock options covering 100,000 ADSs directly under this award.